Atopic Dermatitis Market to Witness Growth by 2034 | Amgen, Kyowa Kirin, Dermira, Eli Lilly and Company, Almirall, Dermavant Sciences, Japan Tobacco Pharmaceutical, Torii Pharmaceutical, Cara Therapeutics, Pfizer, Arena Pharmaceuticals, Arcutis Biotherape

DelveInsight's "Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Atopic Dermatitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Atopic Dermatitis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Atopic Dermatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Atopic Dermatitis market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the atopic dermatitis market report:

In 2023, the total market size for atopic dermatitis across the 7MM was approximately USD 17 billion, with expectations for significant growth by 2034 during the study period (2020-2034). Atopic dermatitis, commonly known as eczema, is a chronic condition characterized by inflammation, redness, and irritation of the skin. While it often begins in childhood, it can affect individuals of any age.

Around 40% of those with atopic dermatitis are aged 18 or younger, and approximately 60% experience early onset, typically between 0 and 2 years of age. The United States reports the highest number of prevalent cases within the 7MM.

Accurate diagnosis of atopic dermatitis is crucial, as about 25% of cases remain undiagnosed or misdiagnosed, leading to significant delays in treatment. Of those diagnosed, over 25% have moderate to severe forms of the disease.

Among the available targeted therapies and biologics, DUPIXENT, the first approved treatment for atopic dermatitis, generates approximately USD 2 billion in revenue by specifically targeting the moderate-to-severe patient population. Another promising category includes JAK inhibitors, with several approved options such as OPZELURA, RINVOQ, CIBINQO, CORECTIM, and OLUMIANT.

Despite a wide range of treatment options, around 40% of patients still rely on over-the-counter medications due to dissatisfaction with the efficacy and safety of prescription drugs. PDE4 inhibitors remain the only viable treatment for patients with mild atopic dermatitis.

Looking ahead, roflumilast is positioned as a potential blockbuster drug, with the US FDA's Prescription Drug User Fee Act (PDUFA) date set for July 2024. In April 2024, Dermavent Sciences announced that the FDA has accepted the Supplemental New Drug Application (sNDA) for VTAMA, a topical treatment for atopic dermatitis.

Additionally, Chugai's MITCHGA (nemolizumab) has been approved in Japan for treating pruritus, a significant symptom of atopic dermatitis, with an anticipated US launch by 2027.

Atopic Dermatitis Overview

Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. It often begins in childhood and can persist into adulthood, though it may also appear for the first time in adults. The condition is associated with a higher risk of developing other allergic conditions, such as asthma and hay fever.

Causes
The exact cause of atopic dermatitis is not fully understood, but several factors contribute to its development:

Genetic Factors: A family history of atopic diseases, such as asthma or allergies, increases the risk.

Immune System Dysfunction: An overactive immune response can lead to inflammation and skin irritation.

Environmental Factors:

Allergens (e.g., pollen, dust mites)
Irritants (e.g., soaps, detergents)
Weather conditions (extreme heat or cold)
Skin Barrier Dysfunction: Individuals with AD often have a compromised skin barrier, leading to increased moisture loss and susceptibility to irritants and allergens.

Signs and Symptoms
Common signs and symptoms of atopic dermatitis include:

Dry, Scaly Skin: Often found on the hands, feet, face, and behind the knees and elbows.
Intense Itching: Itching can be severe, leading to scratching that worsens the condition.
Red or Brownish-Gray Patches: These can appear on various parts of the body.
Thickened Skin: Chronic scratching may lead to lichenification (thickening of the skin).
Small Bumps: These can leak fluid and crust over when scratched.
Skin Infections: Increased risk of bacterial or viral infections due to broken skin.
Diagnosis
Diagnosing atopic dermatitis typically involves:

Medical History: Reviewing symptoms, family history of allergies, and any environmental triggers.

Physical Examination: A healthcare provider examines the skin and looks for characteristic signs.

Allergy Testing: In some cases, skin tests or blood tests may be conducted to identify specific allergens.

Skin Biopsy: Rarely, a biopsy may be performed to rule out other skin conditions.

Treatment Options
Treatment for atopic dermatitis focuses on managing symptoms and preventing flare-ups. Options include:

Topical Treatments:

Moisturizers: Regular use helps maintain skin hydration.
Topical Corticosteroids: Used to reduce inflammation and itching during flare-ups.
Calcineurin Inhibitors: Such as tacrolimus and pimecrolimus, are non-steroidal options for sensitive areas.
Systemic Treatments: For moderate to severe cases, options include:

Oral Corticosteroids: For short-term use during severe flare-ups.
Immunosuppressants: Such as cyclosporine or methotrexate, for long-term management.
Biologics: Newer targeted therapies like dupilumab (Dupixent) that reduce inflammation.
Phototherapy: Controlled exposure to ultraviolet light can help reduce symptoms in some individuals.

Lifestyle and Home Remedies:

Identifying Triggers: Avoiding known irritants and allergens.
Bathing Practices: Short, lukewarm baths followed by immediate application of moisturizer can help.
Education and Support: Providing information about managing the condition and support for coping with the chronic nature of the disease.

Atopic dermatitis is a common but manageable condition. With a combination of proper skincare, medication, and lifestyle adjustments, many individuals can effectively control their symptoms and improve their quality of life. Regular follow-ups with a healthcare provider are essential for ongoing management and treatment adjustments.

Learn more about Atopic Dermatitis, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Atopic Dermatitis Market

In 2023, the total Atopic Dermatitis Market Size in 7MM was around USD 17 billion, which is expected to increase by 2034 during the study period (2020-2034) in the 7MM.
Among the 7MM, the United States accounted for the highest Atopic Dermatitis Market Size in 2023, followed by Japan for atopic dermatitis.
During the forecast period (2024-2034), pipeline candidates such as difelikefalin, orismilast and are expected to drive the rise in Atopic Dermatitis Market Size.
By 2034, DUPIXENT is expected to garner one of the largest Atopic Dermatitis Market Share in the 7MM.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Atopic Dermatitis Epidemiology

The Atopic Dermatitis epidemiology section provides insights into the historical and current Atopic Dermatitis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Atopic Dermatitis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Atopic Dermatitis Epidemiology at: https://www.delveinsight.com/report-store/atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Atopic Dermatitis Drugs Uptake

This section focuses on the uptake rate of the potential Atopic Dermatitis drugs recently launched in the Atopic Dermatitis market or expected to be launched in 2020-2034. The analysis covers the Atopic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Atopic Dermatitis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Atopic Dermatitis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Atopic Dermatitis Pipeline Development Activities

The Atopic Dermatitis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Atopic Dermatitis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Atopic Dermatitis pipeline development activities at: https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Atopic Dermatitis Therapeutics Assessment

Major key companies such as Amgen, Kyowa Kirin, Dermira, Eli Lilly and Company, Almirall, Dermavant Sciences, Japan Tobacco Pharmaceutical, Torii Pharmaceutical, Cara Therapeutics, Pfizer, Arena Pharmaceuticals, Arcutis Biotherapeutics, UNION Therapeutics, Kymab, Sanofi, and others are working proactively in the Atopic Dermatitis Therapeutics market to develop novel therapies which will drive the Atopic Dermatitis treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Atopic Dermatitis Report Key Insights

1. Atopic Dermatitis Patient Population
2. Atopic Dermatitis Market Size and Trends
3. Key Cross Competition in the Atopic Dermatitis Market
4. Atopic Dermatitis Market Dynamics (Key Drivers and Barriers)
5. Atopic Dermatitis Market Opportunities
6. Atopic Dermatitis Therapeutic Approaches
7. Atopic Dermatitis Pipeline Analysis
8. Atopic Dermatitis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Atopic Dermatitis Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Atopic Dermatitis Competitive Intelligence Analysis
4. Atopic Dermatitis Market Overview at a Glance
5. Atopic Dermatitis Disease Background and Overview
6. Atopic Dermatitis Patient Journey
7. Atopic Dermatitis Epidemiology and Patient Population
8. Atopic Dermatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Atopic Dermatitis Unmet Needs
10. Key Endpoints of Atopic Dermatitis Treatment
11. Atopic Dermatitis Marketed Products
12. Atopic Dermatitis Emerging Therapies
13. Atopic Dermatitis Seven Major Market Analysis
14. Attribute Analysis
15. Atopic Dermatitis Market Outlook (7 major markets)
16. Atopic Dermatitis Access and Reimbursement Overview
17. KOL Views on the Atopic Dermatitis Market
18. Atopic Dermatitis Market Drivers
19. Atopic Dermatitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Atopic Dermatitis Market report here: https://www.delveinsight.com/report-store/atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.